Success Metrics

Clinical Success Rate
100.0%

Based on 25 completed trials

Completion Rate
100%(25/25)
Active Trials
0(0%)
Results Posted
100%(25 trials)

Phase Distribution

Ph phase_2
4
16%
Ph phase_1
16
64%
Ph phase_3
5
20%

Phase Distribution

16

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
16(64.0%)
Phase 2Efficacy & side effects
4(16.0%)
Phase 3Large-scale testing
5(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

25 of 25 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

25

all time

Status Distribution
Completed(25)

Detailed Status

Completed25

Development Timeline

Analytics

Development Status

Total Trials
25
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 116 (64.0%)
Phase 24 (16.0%)
Phase 35 (20.0%)

Trials by Status

completed25100%

Recent Activity

0 active trials
Showing 5 of 25
completedphase_1

A Study of LY2216684 and Theophylline in Healthy Subjects

NCT01263106
completedphase_1

A Study of LY2216684 in Healthy Participants

NCT01380691
completedphase_1

A Study of the Effect of LY2216684 on Lorazepam

NCT01275144
completedphase_1

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

NCT01243957
completedphase_1

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
View all 25 trials

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT01263106Phase 1

A Study of LY2216684 and Theophylline in Healthy Subjects

Completed
NCT01380691Phase 1

A Study of LY2216684 in Healthy Participants

Completed
NCT01275144Phase 1

A Study of the Effect of LY2216684 on Lorazepam

Completed
NCT01243957Phase 1

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Completed
NCT01263197Phase 1

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

Completed
NCT01263119Phase 1

A Study of LY2216684 and Warfarin in Healthy Subjects

Completed
NCT01250873Phase 1

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

Completed
NCT01389752Phase 1

A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects

Completed
NCT01389765Phase 1

A Study to Evaluate the Effect of Food on LY2216684

Completed
NCT01460381Phase 1

A Study to Evaluate the Effect of Genotype on LY2216684

Completed
NCT01370499Phase 3

A Study of LY2216684 in Participants With Major Depression Disorder

Completed
NCT01263223Phase 1

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

Completed
NCT01373931Phase 1

A Study of LY2216684 in Healthy Females

Completed
NCT01266590Phase 1

A Study of LY2216684 and Digoxin in Healthy Subjects

Completed
NCT01241435Phase 1

A Study of LY2216684 in Participants With Impaired Hepatic Function

Completed
NCT01263093Phase 1

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Completed
NCT01460407Phase 1

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Completed
NCT01185340Phase 3

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Completed
NCT00420004Phase 2

A Study for Participants With Major Depression

Completed
NCT01187407Phase 3

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25